Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Amplia Therapeutics ( (AU:ATX) ) has issued an update.
Amplia Therapeutics Limited has announced the cessation of 1,000,000 securities due to the expiry of options without exercise or conversion, effective September 2, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative therapies for the treatment of cancer and fibrotic diseases.
Average Trading Volume: 7,259,213
Technical Sentiment Signal: Buy
Current Market Cap: A$82.69M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.